Poly-ADP-Ribose-Polymerase inhibition ameliorates hind limb ischemia reperfusion injury in a murine model of type 2 diabetes

Chandler A. Long, Valy Boloum, Hassan Albadawi, Shirling Tsai, Hyung Jin Yoo, Rahmi Oklu, Mitchell Goldman, Michael T. Watkins

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

INTRODUCTION:: Diabetes is known to increase poly-ADP-ribose-polymerase (PARP) activity and posttranslational poly-ADP-ribosylation of several regulatory proteins involved in inflammation and energy metabolism. These experiments test the hypothesis that PARP inhibition will modulate hind limb ischemia reperfusion (IR) in a mouse model of type-II diabetes and ameliorate the ribosylation and the activity/transnuclear localization of the key glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH). METHODS:: db/db mice underwent 1.5 hours of hind limb ischemia followed by 1, 7, or 24 hours of reperfusion. The treatment group received the PARP inhibitor PJ34 (PJ34) over a 24-hour period; the untreated group received Lactated Ringer (LR) at the same time points. IR muscles were analyzed for indices of PARP activity, fiber injury, metabolic activity, inflammation, GAPDH activity/intracellular localization, and poly-ADP-ribosylation of GAPDH. RESULTS:: PARP activity was significantly lower in the PJ34-treated groups than in the Lactated Ringer group at 7 and 24 hours of reperfusion. There was significantly less muscle fiber injury in the PJ34-treated group than in the Lactated Ringer-treated mice at 24 hours of reperfusion. PJ34 lowered levels of select proinflammatory molecules at 7 hours and 24 hours of IR. There were significant increases in metabolic activity only at 24 hours of IR in the PJ34 group, which temporally correlated with increase in GAPDH activity, decreased GAPDH poly-ADP-ribosylation, and nuclear translocation of GAPDH. CONCLUSIONS:: PJ34 reduced PARP activity, GAPDH ribosylation, and GAPDH translocation; ameliorated muscle fiber injury; and increased metabolic activity after hind limb IR injury in a murine model of type-II diabetes. PARP inhibition might be a therapeutic strategy after IR in diabetic humans.

Original languageEnglish (US)
Pages (from-to)1087-1095
Number of pages9
JournalAnnals of surgery
Volume258
Issue number6
DOIs
StatePublished - Dec 1 2013

Fingerprint

Glyceraldehyde-3-Phosphate Dehydrogenases
Poly(ADP-ribose) Polymerases
Reperfusion Injury
Type 2 Diabetes Mellitus
Reperfusion
Extremities
Ischemia
Adenosine Diphosphate
Muscles
Wounds and Injuries
Inflammation
N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride
Energy Metabolism
Enzymes

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Poly-ADP-Ribose-Polymerase inhibition ameliorates hind limb ischemia reperfusion injury in a murine model of type 2 diabetes. / Long, Chandler A.; Boloum, Valy; Albadawi, Hassan; Tsai, Shirling; Yoo, Hyung Jin; Oklu, Rahmi; Goldman, Mitchell; Watkins, Michael T.

In: Annals of surgery, Vol. 258, No. 6, 01.12.2013, p. 1087-1095.

Research output: Contribution to journalArticle

Long, Chandler A. ; Boloum, Valy ; Albadawi, Hassan ; Tsai, Shirling ; Yoo, Hyung Jin ; Oklu, Rahmi ; Goldman, Mitchell ; Watkins, Michael T. / Poly-ADP-Ribose-Polymerase inhibition ameliorates hind limb ischemia reperfusion injury in a murine model of type 2 diabetes. In: Annals of surgery. 2013 ; Vol. 258, No. 6. pp. 1087-1095.
@article{dc961a35ded747128657d1c015dcf54c,
title = "Poly-ADP-Ribose-Polymerase inhibition ameliorates hind limb ischemia reperfusion injury in a murine model of type 2 diabetes",
abstract = "INTRODUCTION:: Diabetes is known to increase poly-ADP-ribose-polymerase (PARP) activity and posttranslational poly-ADP-ribosylation of several regulatory proteins involved in inflammation and energy metabolism. These experiments test the hypothesis that PARP inhibition will modulate hind limb ischemia reperfusion (IR) in a mouse model of type-II diabetes and ameliorate the ribosylation and the activity/transnuclear localization of the key glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH). METHODS:: db/db mice underwent 1.5 hours of hind limb ischemia followed by 1, 7, or 24 hours of reperfusion. The treatment group received the PARP inhibitor PJ34 (PJ34) over a 24-hour period; the untreated group received Lactated Ringer (LR) at the same time points. IR muscles were analyzed for indices of PARP activity, fiber injury, metabolic activity, inflammation, GAPDH activity/intracellular localization, and poly-ADP-ribosylation of GAPDH. RESULTS:: PARP activity was significantly lower in the PJ34-treated groups than in the Lactated Ringer group at 7 and 24 hours of reperfusion. There was significantly less muscle fiber injury in the PJ34-treated group than in the Lactated Ringer-treated mice at 24 hours of reperfusion. PJ34 lowered levels of select proinflammatory molecules at 7 hours and 24 hours of IR. There were significant increases in metabolic activity only at 24 hours of IR in the PJ34 group, which temporally correlated with increase in GAPDH activity, decreased GAPDH poly-ADP-ribosylation, and nuclear translocation of GAPDH. CONCLUSIONS:: PJ34 reduced PARP activity, GAPDH ribosylation, and GAPDH translocation; ameliorated muscle fiber injury; and increased metabolic activity after hind limb IR injury in a murine model of type-II diabetes. PARP inhibition might be a therapeutic strategy after IR in diabetic humans.",
author = "Long, {Chandler A.} and Valy Boloum and Hassan Albadawi and Shirling Tsai and Yoo, {Hyung Jin} and Rahmi Oklu and Mitchell Goldman and Watkins, {Michael T.}",
year = "2013",
month = "12",
day = "1",
doi = "10.1097/SLA.0b013e31828cced3",
language = "English (US)",
volume = "258",
pages = "1087--1095",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Poly-ADP-Ribose-Polymerase inhibition ameliorates hind limb ischemia reperfusion injury in a murine model of type 2 diabetes

AU - Long, Chandler A.

AU - Boloum, Valy

AU - Albadawi, Hassan

AU - Tsai, Shirling

AU - Yoo, Hyung Jin

AU - Oklu, Rahmi

AU - Goldman, Mitchell

AU - Watkins, Michael T.

PY - 2013/12/1

Y1 - 2013/12/1

N2 - INTRODUCTION:: Diabetes is known to increase poly-ADP-ribose-polymerase (PARP) activity and posttranslational poly-ADP-ribosylation of several regulatory proteins involved in inflammation and energy metabolism. These experiments test the hypothesis that PARP inhibition will modulate hind limb ischemia reperfusion (IR) in a mouse model of type-II diabetes and ameliorate the ribosylation and the activity/transnuclear localization of the key glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH). METHODS:: db/db mice underwent 1.5 hours of hind limb ischemia followed by 1, 7, or 24 hours of reperfusion. The treatment group received the PARP inhibitor PJ34 (PJ34) over a 24-hour period; the untreated group received Lactated Ringer (LR) at the same time points. IR muscles were analyzed for indices of PARP activity, fiber injury, metabolic activity, inflammation, GAPDH activity/intracellular localization, and poly-ADP-ribosylation of GAPDH. RESULTS:: PARP activity was significantly lower in the PJ34-treated groups than in the Lactated Ringer group at 7 and 24 hours of reperfusion. There was significantly less muscle fiber injury in the PJ34-treated group than in the Lactated Ringer-treated mice at 24 hours of reperfusion. PJ34 lowered levels of select proinflammatory molecules at 7 hours and 24 hours of IR. There were significant increases in metabolic activity only at 24 hours of IR in the PJ34 group, which temporally correlated with increase in GAPDH activity, decreased GAPDH poly-ADP-ribosylation, and nuclear translocation of GAPDH. CONCLUSIONS:: PJ34 reduced PARP activity, GAPDH ribosylation, and GAPDH translocation; ameliorated muscle fiber injury; and increased metabolic activity after hind limb IR injury in a murine model of type-II diabetes. PARP inhibition might be a therapeutic strategy after IR in diabetic humans.

AB - INTRODUCTION:: Diabetes is known to increase poly-ADP-ribose-polymerase (PARP) activity and posttranslational poly-ADP-ribosylation of several regulatory proteins involved in inflammation and energy metabolism. These experiments test the hypothesis that PARP inhibition will modulate hind limb ischemia reperfusion (IR) in a mouse model of type-II diabetes and ameliorate the ribosylation and the activity/transnuclear localization of the key glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH). METHODS:: db/db mice underwent 1.5 hours of hind limb ischemia followed by 1, 7, or 24 hours of reperfusion. The treatment group received the PARP inhibitor PJ34 (PJ34) over a 24-hour period; the untreated group received Lactated Ringer (LR) at the same time points. IR muscles were analyzed for indices of PARP activity, fiber injury, metabolic activity, inflammation, GAPDH activity/intracellular localization, and poly-ADP-ribosylation of GAPDH. RESULTS:: PARP activity was significantly lower in the PJ34-treated groups than in the Lactated Ringer group at 7 and 24 hours of reperfusion. There was significantly less muscle fiber injury in the PJ34-treated group than in the Lactated Ringer-treated mice at 24 hours of reperfusion. PJ34 lowered levels of select proinflammatory molecules at 7 hours and 24 hours of IR. There were significant increases in metabolic activity only at 24 hours of IR in the PJ34 group, which temporally correlated with increase in GAPDH activity, decreased GAPDH poly-ADP-ribosylation, and nuclear translocation of GAPDH. CONCLUSIONS:: PJ34 reduced PARP activity, GAPDH ribosylation, and GAPDH translocation; ameliorated muscle fiber injury; and increased metabolic activity after hind limb IR injury in a murine model of type-II diabetes. PARP inhibition might be a therapeutic strategy after IR in diabetic humans.

UR - http://www.scopus.com/inward/record.url?scp=84888137780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888137780&partnerID=8YFLogxK

U2 - 10.1097/SLA.0b013e31828cced3

DO - 10.1097/SLA.0b013e31828cced3

M3 - Article

C2 - 23549425

AN - SCOPUS:84888137780

VL - 258

SP - 1087

EP - 1095

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 6

ER -